Enterococcal Bacteremia
Conditions
Keywords
Enterococcus, Bacteremia
Brief summary
Randomized clinical trial to determine the optimal duration of antibiotic treatment for E. Faecalis or E. faecium bacteraemia, following an innovative DOOR / RADAR (Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)) analysis methodology. Phase IV clinical trial, open-labelled, randomized, pragmatic, multicenter study to demonstrate non-inferiority of a 7-day antibiotic regimen vs. 14 days in the treatment of bacteremia due to E. faecalis or E. faecium.
Detailed description
Phase IV clinical trial, open-labelled, randomized, pragmatic, multicenter study to demonstrate non-inferiority of a 7-day antibiotic regimen vs. 14 days in the treatment of bacteremia due to E. faecalis or E. faecium. Adequate antibiotic regimen is included in the protocol; initially this regimen included ciprofloxacine but this has been modified si that in the last version 3 dated feb 6th ciprofloxacine is not allowed as a possible treatment for these patients. Antibiotic regimen included as possible treatments in the study are the follows: * Isolated strains sensitive to ampicillin: ampicillin 2g/6 or 8h (i.v) * Strains resistant to ampicillin and/or patients with allergy to beta-lactam drugs: * Vancomycin: 15 mg/kg/12h i.v (with determination of trough plasma levels on day 2-3 of treatment if available). * Linezolid: 600 mg/12 hours (i.v) * Daptomycin: 8-10 mg/kg/day (i.v). Intra-abdominal or soft tissue infections meeting study criteria, for which a polymicrobial infection is suspected: Amoxicillin/clavulanic acid (isolates sensitive to ampicillin) 1 g/8h iv - Piperacillin/tazobactam (isolates sensitive to ampicillin) 4 g/8h (i.v.) - Combination of vancomycin, linezolid or daptomycin with a drug active against Gram-negative and anaerobic bacteria to ensure complete coverage in the case of bacteremia with a presumably polymicrobial focus. Oral Treatment: In order to facilitate discharge of patients in both arms and reduce the risk of complications, as well as in keeping with the increasing use of this practice, the option to switch to oral therapy is allowed at the discretion of the responsible clinician, in both arms in patients with hemodynamic stability who tolerate oral treatment, at the discretion of the physician. responsable. \- Amoxicillin 1g/8h or amoxicillin/clavulanic acid 875/125mg/8h if polymicrobial infection is suspected Linezolid 600mg/12h The choice will be in this order, according to the sensitivity of the isolate and allergies or other common circumstances for the use of these drugs. The previous version allowed the use of cipro at the discretion of the clinicians as a sequential treatment option based on the fact that it is a clinical trial for low-risk bacteraemias in order to facilitate early sequential treatment (and thus avoid unnecessarily prolonging the hospital admissions.We decided to withdraw it on the basis that currently the EUCAST breakpoints only apply to urinary tract infections.The direct consequence is that the number of sequential treatment options is reduced.
Interventions
DRUGShort-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
DRUGLong-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.
Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
Sponsors
Spanish Network for Research in Infectious Diseases
Spanish Clinical Research Network - SCReN
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomised, multicentre, phase IV open trial of real clinical practice
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients (18 years of age or older) hospitalised with monomicrobial E. faecalis or E. faecium bacteremia. * Negative follow-up blood cultures performed between days 2 and 3 of active treatment. * Disappearance of fever (\>37.8ºC) within the first 72 hours. * Signed informed consent. The previous version allowed this inclusion criterion Early adequate control of the source of bacteremia within 72 hours in the cases in which it is feasible and necessary (urinary or biliary tract release; abscess drainage; catheter-removal, etc), which is now removed because it is already an exclusion criterion.
Exclusion criteria
* patients with polymicrobial bacteremia * Patients with limited life expectancy in whom only conservative clinical management had been decided. * Hemodynamic instability on day 5-6 after the start of active treatment. * Patients wearing endovascular devices or prosthetic heart valves. * Source of uncontrolled bacteremia adequately defined as undrained abscess, bile duct infection associated with plastic prostheses not removed or not replaced within the first 72 hours of bacteraemia, other infections related to non-removed prostheses, prostatitis, and infective endocarditis, as well as infections that require prolonged treatment, such as joint and bone infections. * Existence of a secondary focus, different from the initial one, or presence of metastatic focus of infection. * Severe neutropenia (\<500 cells / mm3) at the time of bacteremia diagnosis. * Pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical success | TOC (Test of cure) visit (performed at day 28-32 after the end of suitable antibiotic treatment) or if drainage occurs after day 7 of treatment, TOC is to be done 7 days after that day. | Clinical success , composite endpoint defined as all the following: (a) survival at TOC; (b) absence of enterococcal bacteremia relapse or infective endocarditis diagnosis at TOC; (c) no need to prolong therapy beyond the pre-established duration, or restart drugs against enterococci for any reason within 30 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival | TOC visit (day 28-32) and follow-up visit at day 90 | Number of live patients |
| Length of hospital stay | From patient first day inhospital (day of admission) until patient hospital discharge due to cure or home follow up assessed up to 30 days of the initiation of antibiotic administration | Number of days patient is in-hospital |
| Duration of intravenous and total therapy | From date of randomization until the last follow up visit planned 30 days of the initiation of antibiotic administration | Number of days of intravenous and total therapy in the CEP (Clinically Evaluable Population) |
| Rates of relapse or infective endocarditis diagnosis | TOC visit (day 28-32 ) and follow-up visit at day 90 | Rates of relapse or infective endocarditis diagnosis in the CEP (Clinically Evaluable Population) |
| Number of participants with Adverse Events due to antibiotic treatment | From date of randomization until the last follow up visit planned 90 days of the initiation of antibiotic administration | Registration of all adverse events happening form the signature on informed consent form to 30 days after the study drugs administration. |
| Incidence of secondary infections | TOC visit (on day 28-32) and follow-up visit at day 90 | Number of patients with recurrent bacteremia |
| Change in SOFA score (Sepsis related Organ Failure Assessment) | Visit 0 (baseline) and TOC visit (on day 28-32) and follow-up visit at day 90 | Calculation of the SOFA score valued from 0 to 4 (0 best to 4 worst punctuation) |
| Incidence of diarrhoea by C. difficile | From date of randomization until the last follow up visit planned 30 days of the initiation of antibiotic administration | To evaluate the frequency of diarrhea by C. difficile |
Countries
Spain
Contacts
Primary ContactClara María Rosso Fernández
Backup ContactIrene Borreguero Borreguero
Outcome results
None listed